ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment

ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment PR Newswire LONDON, July 18, 2012 - ViiV Healthcare Collaborates with Clinton Health Access Initiative (CHAI) & Mylan Pharmaceuticals on First-of-its-Kind Agreement to Provide a Paediatric Dispersible Fixed Dose Combination for Treatment of HIV - Establishes Five New Partnerships to Promote Paediatric HIV Research, Treatment and Care Initiatives LONDON, July 18, 2012 /PRNewswire/ -- ViiV Healthcare today announced a broad range of groundbreaking initiatives as part of its ongoing commitment to address the gaps in care and treatment of paediatric HIV. These efforts are part of the company's Paediatric Innovation Seed Fund. They include a public- private partnership with CHAI and Mylan Laboratories Limited, a subsidiary of US-based Mylan Inc., to submit a registration file for a new dispersible formulation of a fixed dose combination for paediatric patients in resource-limited settings. ViiV Healthcare is also providing grants of nearly 3 million pounds to five organisations to improve paediatric HIV research, care and treatment access in resource-limited settings. Taken together, these new initiatives bring ViiV Healthcare's level of support to approximately 5.3 million pounds of the total 10 million pounds committed since the introduction of the Paediatric Innovation Seed Fund in 2009.